[Medullary thyroid cancer, a tumour with many appearances]

Ned Tijdschr Geneeskd. 2010:154:A1818.
[Article in Dutch]

Abstract

Medullary thyroid cancer (MTC) has a variable clinical presentation. We present 3 patients with this endocrine tumour. The first patient, a 41-year-old woman complaining of diarrhoea, a painful abdomen, weight loss and sensibility disorders in both legs, had metastases of MTC in the spine, with little progression during 2 years of follow-up. The second patient, a 64-year-old woman suffering from a painful nodule in the neck and a painful shoulder, was diagnosed with MTC and liver, lung and bone metastases. She died after 14 months due to progressive disease. The third patient, an 81-year-old woman with hyperparathyroidism, was coincidentally diagnosed with MTC after goitre surgery at the age of 67. When she was evaluated for rising calcitonin levels, a pheochromocytoma was found. RET mutation analysis confirmed a MEN2A syndrome. Current diagnostic procedures of MTC may include positron emission tomography with 18F-deoxyglucose (FDG-PET) and 18F-diphenylalanine (DOPA-PET). MTC is usually treated surgically. Tyrosine kinase inhibitors appear to offer potential new therapeutic possibilities.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Aged, 80 and over
  • Diagnosis, Differential
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Metastasis
  • Positron-Emission Tomography
  • Pyrazoles / therapeutic use
  • Pyrimidines / therapeutic use
  • Thyroid Neoplasms / diagnosis*
  • Thyroid Neoplasms / drug therapy
  • Thyroid Neoplasms / surgery*
  • Thyroid Nodule / diagnosis
  • Thyroid Nodule / drug therapy
  • Thyroid Nodule / surgery
  • Treatment Outcome

Substances

  • 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine
  • Enzyme Inhibitors
  • Pyrazoles
  • Pyrimidines